Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 8/2008

01-10-2008 | Original Paper

Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California

Authors: Arti Parikh-Patel, Richard H. White, Mark Allen, Rosemary Cress

Published in: Cancer Causes & Control | Issue 8/2008

Login to get access

Abstract

Objective

We conducted a retrospective cohort study to examine cancer risk in a large cohort of systemic lupus erythematosus (SLE) patients in California.

Methods

The cohort consisted of individuals with SLE derived from statewide patient discharge data during the period 1991–2002. SLE patients were followed using cancer registry data to examine patterns of cancer development. Standardized incidence ratios (SIRs) and 95% CI were calculated to compare the observed to expected numbers of cancers based on age-, race-, and sex-specific incidence rates in the California population.

Results

The 30,478 SLE patients were observed for 157,969 person-years. A total of 1,273 cancers occurred within the observation interval. Overall cancer risk was significantly elevated (SIR = 1.14, 95% CI = 1.07–1.20). SLE patients had higher risks of vagina/vulva (SIR = 3.27, 95% CI = 2.41–4.31) and liver cancers (SIR = 2.70, 95% CI = 1.54–4.24). Elevated risks of lung, kidney, and thyroid cancers and several hematopoietic malignancies were also observed. Individuals had significantly lower risks of several screenable cancers, including breast, cervix, and prostate.

Conclusions

These data suggest that risks of several cancer types are elevated among SLE patients. Detailed studies of endogenous and exogenous factors that drive these associations are needed.
Literature
1.
Abu-Shakra M, Buskila D, Shoenfeld Y (2000) SLE and cancer. In: Shoenfeld Y, Gershwin ME (eds) Cancer and autoimmunity. Elsevier Science, pp 31–40
2.
Abu-Shakra M, Gladman DD, Urowitz MB (2004) Mortality studies in SLE: how far can we improve survival of patients with SLE. Autoimmun Rev 3:418–420PubMedCrossRef
3.
Stahl-Hallengren C, Jonsen A, Nived O, Sturfelt G (2000) Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 27:685–691PubMed
4.
Urowitz MB, Gladman DD (2000) How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology (Oxford) 39:238–244CrossRef
5.
Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT (1997) Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol 24:1061–1065PubMed
6.
Bernatsky S, Boivin JF, Joseph L et al (2005) An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52:1481–1490PubMedCrossRef
7.
Bernatsky S, Ramsey-Goldman R, Rajan R et al (2005) Non-Hodgkin’s lymphoma in systemic lupus erythematosus. Ann Rheum Dis 64:1507–1509PubMedCrossRef
8.
Bjornadal L, Lofstrom B, Yin L, Lundberg IE, Ekbom A (2002) Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 31:66–71PubMedCrossRef
9.
Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH (1997) Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 40:761–768PubMedCrossRef
10.
Pettersson T, Pukkala E, Teppo L, Friman C (1992) Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 51:437–439PubMedCrossRef
11.
Ragnarsson O, Grondal G, Steinsson K (2003) Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus 12:687–691PubMedCrossRef
12.
Xu Y, Wiernik PH (2001) Systemic lupus erythematosus and B-cell hematologic neoplasm. Lupus 10:841–850PubMedCrossRef
13.
Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165:2337–2344PubMedCrossRef
14.
Ramsey-Goldman R, Mattai SA, Schilling E et al (1998) Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med 46:217–222PubMed
15.
Sweeney DM, Manzi S, Janosky J et al (1995) Risk of malignancy in women with systemic lupus erythematosus. J Rheumatol 22:1478–1482PubMed
16.
17.
Bernatsky S, Clarke A, Ramsey-Goldman R (2002) Malignancy and systemic lupus erythematosus. Curr Rheumatol Rep 4:351–358PubMedCrossRef
18.
Oertel SH, Riess H (2002) Immunosurveillance, immunodeficiency and lymphoproliferations. Recent Results Cancer Res 159:1–8PubMed
19.
Bhalla R, Ajmani HS, Kim WW, Swedler WI, Lazarevic MB, Skosey JL (1993) Systemic lupus erythematosus and Hodgkin’s lymphoma. J Rheumatol 20:1316–1320PubMed
20.
Black KA, Zilko PJ, Dawkins RL, Armstrong BK, Mastaglia GL (1982) Cancer in connective tissue disease. Arthritis Rheum 25:1130–1133PubMedCrossRef
21.
Canoso JJ, Cohen AS (1974) Malignancy in a series of 70 patients with systemic lupus erythematosus. Arthritis Rheum 17:383–390PubMedCrossRef
22.
23.
Abu-Shakra M, Gladman DD, Urowitz MB (1996) Malignancy in systemic lupus erythematosus. Arthritis Rheum 39:1050–1054PubMedCrossRef
24.
Cibere J, Sibley J, Haga M (2001) Systemic lupus erythematosus and the risk of malignancy. Lupus 10:394–400PubMedCrossRef
25.
Nived O, Bengtsson A, Jonsen A, Sturfelt G, Olsson H (2001) Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus 10:500–504PubMedCrossRef
26.
Sultan SM, Ioannou Y, Isenberg DA (2000) Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology (Oxford) 39:1147–1152CrossRef
27.
Services USDoHaH (2000) ICD-9-CM: international classification of diseases, 9th Revision, Clinical modification, 6th edition, Washington DC
28.
Cancer Reporting in California (1997) Standards for automated reporting. California cancer reporting system standards, vol II. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, December 1997
29.
Cancer Reporting in California (1997) Data standards for regional registries and California Cancer Registry. California cancer reporting system standards, vol III. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, December 1997
30.
Cancer Reporting in California (1998) Reporting procedures for physicians. California cancer reporting system standards, vol IV. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, January 1998
31.
Cancer Reporting in California (1997) Abstracting and coding procedures for hospitals. California cancer reporting system standards, vol I. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, June 1997
32.
Chen VW, Howe HL, Wu XC (2000) Cancer in North America, 1993–1997. Volume I: incidence. North American Association of Central Cancer Registries, Springfield
33.
Seiffert JE, Price WT, Gordon B (1990) The California tumor registry: a state-of-the-art model for a regionalized, automated, population-based registry. Top Health Rec Manage 11:59–73PubMed
34.
Integrity Program (1999) Data reengineering environment software. Vality Technology Inc., Boston
35.
Allen M (2001) Validation of OSHPD and CCR insurance status. California Association of Central Cancer Registries Technical Conference, Riverside, CA
36.
Fritz A, Percy C, Jack A et al (2000) International classification of diseases for oncology, 3rd edn. World Health Organization, Geneva
37.
Breslow NE, Day NE (1987) Statistical methods in cancer research, Volume II: the design and analysis of cohort studies. International Agency for Research on Cancer, Lyon
38.
Bernatsky S, Boivin JF, Joseph L et al (2002) Prevalence of factors influencing cancer risk in women with lupus: social habits, reproductive issues, and obesity. J Rheumatol 29:2551–2554PubMed
39.
Bruce IN, Gladman DD, Urowitz MB (1998) Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. Clin Exp Rheumatol 16:435–440PubMed
40.
McAlindon T, Giannotta L, Taub N, D’Cruz D, Hughes G (1993) Environmental factors predicting nephritis in systemic lupus erythematosus. Ann Rheum Dis 52:720–724PubMedCrossRef
41.
Petri M, Perez-Gutthann S, Spence D, Hochberg MC (1992) Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93:513–519PubMedCrossRef
42.
Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J Jr (1999) Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 26:2363–2368PubMed
43.
Ahmed MM, Berney SM, Wolf RE et al (2006) Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus. Am J Med Sci 331:252–256PubMedCrossRef
44.
Berthier S, Mougin C, Vercherin P et al (1999) Does a particular risk associated with papillomavirus infections exist in women with lupus? Rev Med Interne 20:128–132PubMed
45.
Tam LS, Chan AY, Chan PK, Chang AR, Li EK (2004) Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 50:3619–3625PubMedCrossRef
46.
Thomas RH, Ridley CM, Black MM (1985) Lichen sclerosus et atrophicus associated with systemic lupus erythematosus. J Am Acad Dermatol 13:832–833PubMedCrossRef
47.
Gibbons RB, Westerman E (1988) Acute nonlymphocytic leukemia following short-term, intermittent, intravenous cyclophosphamide treatment of lupus nephritis. Arthritis Rheum 31:1552–1554PubMedCrossRef
48.
Lishner M, Hawker G, Amato D (1990) Chronic lymphocytic leukemia in a patient with systemic lupus erythematosus. Acta Haematol 84:38–39PubMed
49.
Rosenthal NS, Farhi DC (1996) Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy. Am J Clin Pathol 106:676–679PubMed
50.
Vasquez S, Kavanaugh AF, Schneider NR, Wacholtz MC, Lipsky PE (1992) Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. J Rheumatol 19:1625–1627PubMed
51.
Elliott RW, Essenhigh DM, Morley AR (1982) Cyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefit. Br Med J (Clin Res Ed) 284:1160–1161
52.
Ortiz A, Gonzalez-Parra E, Alvarez-Costa G, Egido J (1992) Bladder cancer after cyclophosphamide therapy for lupus nephritis. Nephron 60:378–379PubMed
53.
Thrasher JB, Miller GJ, Wettlaufer JN (1990) Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis. J Urol 143:119–121PubMed
54.
Bernatsky S, Boivin JF, Joseph L et al (2005) Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum 53:781–784PubMedCrossRef
55.
Alarcon GS, Calvo-Alen J, McGwin G et al (2006) Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis 65(9):1168–1174PubMedCrossRef
56.
Bernatsky SR, Cooper GS, Mill C, Ramsey-Goldman R, Clarke AE, Pineau CA (2006) Cancer screening in patients with systemic lupus erythematosus. J Rheumatol 33:45–49PubMed
57.
Katz JN, Barrett J, Liang MH et al (1997) Sensitivity and positive predictive value of Medicare Part B physician claims for rheumatologic diagnoses and procedures. Arthritis Rheum 40:1594–1600PubMedCrossRef
58.
Löfström B, Backlin C, Sundström C, Ekbom A, Lundberg IE (2007) A closer look at non-Hodgkin’s lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis 66(12):1627–1632PubMedCrossRef
59.
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef
Metadata
Title
Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California
Authors
Arti Parikh-Patel
Richard H. White
Mark Allen
Rosemary Cress
Publication date
01-10-2008
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 8/2008
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9151-8

Other articles of this Issue 8/2008

Cancer Causes & Control 8/2008 Go to the issue

Original Paper

Deaths from non-melanoma skin cancer in Western Australia

Original Paper

Unpasteurized milk consumption and subsequent risk of cancer

Original Paper

Dietary factors and risk of t(14;18)-defined subgroups of non-Hodgkin lymphoma

Review Article

Systematic review of prostate cancer’s association with body size in childhood and young adulthood

Original Paper

History of benign breast disease and risk of breast cancer among women in China: a case–control study

Original Paper

Lymphoma survival patterns by WHO subtype in the United States, 1973–2003
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits